SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending following an FDA advisory committee's unanimous vote of confidence in its mRNA-1010 flu vaccine for adults aged 50 and older. The community is actively discussing the potential for a successful product launch, a broader shift into oncology, and institutional positioning through call spread strategies despite ongoing polarized debate regarding vaccine efficacy.

Horizon Quantum Holdings Ltd. engages in the development of software tools. The company is headquartered in Singapore.

Horizon Quantum Holdings Ltd. - Ordinary Shares - Class A

Horizon Quantum Holdings is generating significant buzz due to its role as a pure-play quantum software firm, with investors closely watching its strategic hardware-agnostic platform and strong backing from industry majors like IonQ and Dell. The community is actively debating the stock's low-float volatility and its long-term potential to serve as the critical infrastructure layer for quantum computing.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is gaining significant market attention as investors weigh promising clinical data for its rezpegaldesleukin (rezpeg) program in atopic dermatitis and alopecia areata against concerns regarding recent equity offerings. Community sentiment remains polarized, with bullish investors betting on the drug's long-term competitive durability and potential for partnerships, while others express frustration over share dilution and the ongoing legal conflict with Eli Lilly.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is gaining momentum as investors closely monitor developments regarding potential tenant signings for the company's energy-intensive data center infrastructure projects in Texas. The community is actively debating the company's governance and the impact of recent high-profile management conflicts on the stock's future, while excitement builds around its strategic pivot toward high-demand AI power requirements.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is drawing investor attention as community members debate its potential as a 'pipeline-in-a-product' candidate, driven by its selective ITK inhibitor, soquelitinib. While the community is actively discussing ongoing clinical trials, the impact of recent institutional stake updates, and potential acquisition interest, others remain skeptical about the stock's long-term performance given the highly competitive immunology sector.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is experiencing a wave of community discussion fueled by speculation regarding potential integration with other high-profile tech ventures and general excitement about a market comeback. Investors are actively debating the coin's long-term utility versus its status as a meme-driven asset while tracking technical price levels during a period of high volatility.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is trending as investors react to the confirmed start of pre-orders for Grand Theft Auto VI, a major commercial milestone for the highly anticipated title. The community is actively discussing the stock's potential as a long-term revenue engine, with many retail investors expressing strong bullish sentiment regarding the game's massive sales potential and its impact on the company's valuation.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML is trending due to heightened scrutiny following unverified U.S. government concerns regarding potential export control violations related to its advanced lithography equipment reaching China. While the community is actively debating the credibility of these claims and the potential for regulatory impact, many traders view any associated price weakness as a buying opportunity given the company's entrenched market position and massive backlog.

Delta Air Lines, Inc. engages in the provision of scheduled air transportation for passengers and cargo. It operates through the Airline and Refinery segments. The Airline segment provides scheduled air transportation for passengers and cargo. The Refinery segment provides jet fuel to the airline segment. The company was founded by Collett Everman Woolman in 1928 and is headquartered in Atlanta, GA.

Delta Air Lines, Inc.

Delta is trending as investors react to a positive revenue outlook and resilient demand, even as the broader airline sector grapples with margin pressure from rising jet fuel costs. The community is actively debating the sustainability of these gains against the backdrop of geopolitical uncertainty and the industry's ability to maintain premium pricing power.

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

Immix Biopharma is currently experiencing heightened investor focus following the FDA's Breakthrough Therapy Designation for NXC-201 and ongoing anticipation surrounding final clinical trial data. The community is actively discussing the stock's potential as a takeover target, the strategic significance of the company's manufacturing advantages, and the expected path toward a BLA filing later this year.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Jade Biosciences Stock Trading Lower On Monday?

Jade Biosciences reports Phase 1 JADE101 data showing sustained IgA reductions in IgAN, while analyst addresses ADA concerns and timeline expectations.read more...

Jade Biosciences (NASDAQ:JBIO) Stock Price Down 9.6% - Here's What Happened

Jade Biosciences (NASDAQ:JBIO) Shares Down 9.6% - Here's What Happened...

Jade Biosciences (NASDAQ:JBIO) Sets New 1-Year High - Here's What Happened

Jade Biosciences (NASDAQ:JBIO) Hits New 52-Week High - What's Next...

FY2028 Earnings Forecast for JBIO Issued By HC Wainwright

Jade Biosciences, Inc. (NASDAQ:JBIO - Free Report) - Equities research analysts at HC Wainwright issued their FY2028 EPS estimates for Jade Biosciences in a report issued on Monday, April 27th. HC Wainwright analyst A. He forecasts that the company will post earnings of ($2.17) per share for the yea...

Jade Biosciences, Inc. (NASDAQ:JBIO) Short Interest Update

Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totaling 3,061,277 shares, an...

Jade Biosciences (NASDAQ:JBIO) Shares Up 9.7%  - What's Next?

Jade Biosciences (NASDAQ:JBIO) Shares Up 9.7% - Should You Buy...

Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) saw a large decline in short interest in March. As of March 31st, there was short interest totaling 1,251,725 shares, a decline of 18.5% from...

Jade Biosciences (NASDAQ:JBIO) Stock Price Up 9.7% - Should You Buy?

Jade Biosciences (NASDAQ:JBIO) Stock Price Up 9.7% - Here's What Happened...

Jade Biosciences (NASDAQ:JBIO) Rating Increased to Hold at Zacks Research

Zacks Research raised Jade Biosciences from a "strong sell" rating to a "hold" rating in a report on Wednesday...

Jade Biosciences (NASDAQ:JBIO) Trading Up 7.9% - What's Next?

Jade Biosciences (NASDAQ:JBIO) Stock Price Up 7.9% - What's Next...

Jade Biosciences, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.

Jade Biosciences Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

JBIOJade Biosciences Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest JBIO News